EP Patent

EP2507231A1 — Indazole derivatives as pi 3 - kinase inhibitors

Assigned to Glaxo Group Ltd · Expires 2012-10-10 · 14y expired

What this patent protects

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

USPTO Abstract

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

Drugs covered by this patent

Patent Metadata

Patent number
EP2507231A1
Jurisdiction
EP
Classification
—
Expires
2012-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Glaxo Group Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.